ABBV Earnings Prediction
The chart below shows how ABBV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABBV sees a -1.36% change in stock price 10 days leading up to the earnings, and a -0.07% change 10 days following the report. On the earnings day itself, the stock moves by -0.29%. This data can give you a slight idea of what to expect for the next quarter's release.
ABBV Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
14.46B
3.83%
-0.01%
Gross Margin
70.87%
3.22%
-0.10%
Operating Margin
27.27%
-15.91%
-20.86%
Net Margin
10.82%
-15.40%
14.01%
EPS
0.88
-12.00%
14.29%
No Data Available
ABBV Earnings Analysis
ABBVIE INC. Corporation (ABBV.N) Earnings Conference Call
Positive
Sales Revenue Surge: 1. Strong Sales Growth: AbbVie reported total net revenues of nearly $14.5 billion, reflecting robust growth of 4.9% on an operational basis, with the ex-Humira growth platform delivering reported growth of nearly 18%.
Revenue Guidance Increase: 2. Increased Revenue Guidance: The company raised its full-year revenue guidance by $500 million, now expecting total net revenues of approximately $56 billion, marking an increase of $1.8 billion since initial guidance in February.
Immunology Sales Surge: 3. Impressive Product Performance: Skyrizi and Rinvoq combined sales are expected to exceed $17 billion this year, which is $1.3 billion above initial expectations, showcasing strong momentum in the immunology segment.
Increased EPS Guidance: 4. Raising EPS Guidance: AbbVie increased its full-year adjusted earnings per share guidance by $0.15, now expecting adjusted EPS between $10.90 and $10.94, reflecting strong operational performance.
Dividend Growth Announcement: 5. Dividend Increase: AbbVie announced a 5.8% increase in its quarterly cash dividend, beginning with the dividend payable in February 2025, demonstrating a commitment to returning value to shareholders.
Negative
Humira Sales Decline: 1. Declining Humira Sales: Humira global sales decreased by 36.5% on an operational basis, totaling $2.2 billion, due to increased biosimilar competition and unexpected volume shifts to other novel mechanisms.
Aesthetics Sales Drop: 2. Aesthetics Revenue Decline: Global aesthetics sales fell by $200 million, primarily driven by lower Juvederm volume, which continues to be impacted by challenging economic conditions in key markets.
Juvederm Sales Outlook Adjustment: 3. Juvederm Sales Outlook Moderation: The company has moderated its Juvederm sales outlook for the year due to ongoing economic challenges affecting consumer spending in the aesthetics market, particularly in China.
Vraylar Sales Adjustment: 4. Vraylar Revenue Adjustment: Vraylar total sales were adjusted down by $100 million, reflecting continued strong prescription demand but negatively impacted by a modestly unfavorable channel mix.
Net Interest Expense Impact: 5. Increased Net Interest Expense: AbbVie reported a net interest expense of $591 million, which could pressure overall profitability and cash flow management.
ABBV FAQs
How does ABBV typically perform around its earnings report dates?
Is AbbVie Inc. (ABBV) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ABBV Earning Call Sentiment
AbbVie Inc. (ABBV) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ABBV.N
3.88%Positive
The earnings call summary shows strong financial performance with increased sales projections for key drugs like Skyrizi and Rinvoq, and a raised full-year revenue and EPS guidance. The Q&A section reflects confidence in growth despite Humira's decline, and no major risks were highlighted. The dividend increase and debt repayment plan are positive signals. Adjustments based on critical factors such as positive guidance and strong earnings suggest a positive stock price movement, likely in the range of 2% to 8%.